Business Context and Reporting Period
This Form 8-K was filed by AntriaBio, Inc. (not Rezolute, Inc.) on March 2, 2016, reporting events occurring on February 29, 2016. The filing details a strategic collaboration and a concurrent equity financing event.
Key Financial Metrics and Transactions
- Collaboration Agreement: Entered into a Strategic Collaboration and License Agreement with pH Pharma Co., Ltd. ("PH") on February 29, 2016.
- Licensing Terms: PH received a conditional exclusive license to manufacture and sell AntriaBio's lead product candidate, AB101, in seven Asian countries (Korea, Cambodia, Laos, Myanmar, Thailand, Malaysia, Singapore, and Vietnam).
- License Conditions: The license becomes effective only after PH purchases a minimum of $8 million of AntriaBio securities.
- Equity Offering (Series A Preferred Stock):
- PH agreed to purchase $1 million of Series A Preferred Stock immediately.
- PH must purchase an additional $1 million of Series A Preferred Stock by March 31, 2016.
- PH must purchase at least $6 million of Common Stock in private placement transactions at negotiated prices.
- Additional Close Proceeds: On March 2, 2016, the company completed an additional close of the Series A Preferred Stock offering with six accredited investors (including PH).
- Gross Cash Proceeds: Approximately $3.3 million (excluding fees and expenses).
- Shares Issued: 1,716,667 Offered Shares.
- Price Per Share: $1.95.
- Placement Agent Compensation:
- Cash: Approximately $165,000 (7% of the purchase price from investors introduced by the agent).
- Warrants: Issued warrants to purchase 120,385 shares of common stock at an exercise price of $2.34 per share (representing 10% of shares issued to agent-introduced investors).
Material Changes and Outlook
The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as it is a Current Report focused on specific corporate events. The primary material change is the expansion of the company's commercial footprint into Asia contingent upon the completion of the $8 million investment by pH Pharma. Management intends to explore further opportunities utilizing the proprietary microsphere platform with PH.
Risks and Contingencies
- Conditional License: The exclusive license for AB101 in the designated Asian territories is not yet effective. It is contingent upon pH Pharma completing the full $8 million investment obligation.
- Unregistered Securities: The securities sold in this transaction were exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. They may not be offered or sold in the United States absent registration or an applicable exemption.
- Future Pricing: The price for the required $6 million Common Stock purchase is subject to negotiation in good faith based on commercially reasonable terms, introducing uncertainty regarding final valuation.
Investor Verification Checklist
- Verify the status of the remaining $7 million investment obligation by pH Pharma (specifically the $1 million Series A tranche due by March 31, 2016, and the $6 million Common Stock tranche).
- Confirm the exact terms of the "commercially reasonable" pricing for the future Common Stock purchase.
- Review the full text of the Collaboration Agreement (Exhibit 10.1) for specific milestones, royalty terms, or termination clauses not summarized in the 8-K.
- Assess the impact of the 120,385 warrants issued to the placement agent on future dilution.